Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Corcept Therapeutics stock

CORT
US2183521028
529882

Price

52.64
Today +/-
+0.77
Today %
+1.56 %
P

Corcept Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Corcept Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Corcept Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Corcept Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Corcept Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Corcept Therapeutics Stock Price History

DateCorcept Therapeutics Price
11/18/202452.64 undefined
11/15/202451.83 undefined
11/14/202454.79 undefined
11/13/202458.26 undefined
11/12/202457.79 undefined
11/11/202459.06 undefined
11/8/202459.60 undefined
11/7/202454.30 undefined
11/6/202454.23 undefined
11/5/202452.14 undefined
11/4/202450.06 undefined
11/1/202447.62 undefined
10/31/202448.97 undefined
10/30/202446.89 undefined
10/29/202448.21 undefined
10/28/202448.34 undefined
10/25/202447.28 undefined
10/24/202447.24 undefined
10/23/202448.06 undefined
10/22/202448.92 undefined
10/21/202449.11 undefined

Corcept Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Corcept Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Corcept Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Corcept Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Corcept Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Corcept Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Corcept Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Corcept Therapeutics’s growth potential.

Corcept Therapeutics Revenue, EBIT and net profit per share

DateCorcept Therapeutics RevenueCorcept Therapeutics EBITCorcept Therapeutics Net Income
2029e1.36 B undefined0 undefined473.99 M undefined
2028e1.05 B undefined457.44 M undefined321.7 M undefined
2027e917.94 M undefined352.12 M undefined237.8 M undefined
2026e1.14 B undefined496.09 M undefined404.52 M undefined
2025e826.28 M undefined252.17 M undefined187.03 M undefined
2024e705.67 M undefined141.52 M undefined145.35 M undefined
2023482.38 M undefined107.28 M undefined106.14 M undefined
2022401.9 M undefined112.6 M undefined101.4 M undefined
2021366 M undefined124.5 M undefined112.5 M undefined
2020353.9 M undefined128.2 M undefined106 M undefined
2019306.5 M undefined111.6 M undefined94.2 M undefined
2018251.2 M undefined89.5 M undefined75.4 M undefined
2017159.2 M undefined52.9 M undefined129.1 M undefined
201681.3 M undefined10.2 M undefined8.1 M undefined
201550.3 M undefined-3.4 M undefined-6.4 M undefined
201426.6 M undefined-27.6 M undefined-31.4 M undefined
201310.4 M undefined-41.5 M undefined-46 M undefined
20123.3 M undefined-36.3 M undefined-38 M undefined
20110 undefined-32.3 M undefined-32.4 M undefined
20100 undefined-27.5 M undefined-26 M undefined
20090 undefined-20.3 M undefined-20.2 M undefined
2008200,000 undefined-19.7 M undefined-20.1 M undefined
2007500,000 undefined-12.2 M undefined-11.6 M undefined
2006300,000 undefined-25.6 M undefined-24.9 M undefined
20050 undefined-21.2 M undefined-20.1 M undefined
20040 undefined-16 M undefined-15.5 M undefined

Corcept Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000000000.010.030.050.080.160.250.310.350.370.40.480.710.831.140.921.051.36
--------------233.33160.0092.3162.0096.3057.8621.9115.363.689.5620.2046.2717.1638.01-19.5614.6129.31
-------------100.00100.0096.1596.0097.5397.4898.0198.3798.5898.3698.7598.5567.3857.5141.6751.8045.2034.95
0000000000000310254879155246301348360396475000000
0-1-7-18-9-15-20-24-11-20-20-26-32-38-46-31-681297594106112101106145187404237321473
--600.00157.14-50.0066.6733.3320.00-54.1781.82-30.0023.0818.7521.05-32.61-80.65-233.331,512.50-41.8625.3312.775.66-9.824.9536.7928.97116.04-41.3435.4447.35
3.55.666.78.118.422.622.834.346.752.468.383.39399.8101106.9116.1124.5126.7122.6124.2126116111.74000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Corcept Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Corcept Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                               
12321.511.637.429.19.517.418.323.924.639.69354.924.240.451.588.7206.8276440.7223.5431.7368.22
0000000000000.61.43.36.29.915.317.619.926.227.631.141.12
0000000000000000012.9000000
0000000000000.91.11.21.72.34.64.75.44.956.17.73
00.70.20.20.80.40.30.31.30.60.40.10.60.91.40.622.77.766.710.330.441.56
123.721.711.838.229.59.817.719.624.52539.795.158.330.148.965.7124.2236.8307.3478.5266.4499.3458.64
000000.10000000.20.20.20.10.20.50.74.54.21.51.80.32
00009.50.50000000000015.3039.436.2112.34.957.18
000000000000000000000000
000000000000000000000000
000000000000000000000000
00.60000.10.10.10.20.10.1044.64.22.82.980.674.261.152.943.577.5105.39
00.6009.50.70.10.10.20.10.104.24.84.42.93.196.474.910593.3157.384.2162.88
124.321.711.847.730.29.917.819.824.625.139.799.363.134.551.868.8220.6311.7412.3571.8423.7583.5621.52
                                               
0041.741.700000.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.13
2.240.910.48.7101.2100.8105124.7146.9172.3197.4243.3308.3313.5320.5348.8363.5384.1417.2457.1516.1591.3662.3738.52
-2.2-9.9-28.1-37.9-53.5-73.6-98.4-110-130.1-150.2-176.2-208.6-246.6-292.6-324-330.4-322.3-193.1-117.7-23.682.5195296.4402.53
-200-8,600-4,300-2,300-1,800-700-2000000000000-100-100300400-200-900609
000000000000000000000000
-00.020.020.010.050.030.010.010.020.020.020.030.060.02-00.020.040.190.30.430.60.790.961.14
0.10.90.80.30.60.50.91.11.31.30.83.63.82.41.91.32.38.68.37.510.66.91217.4
0.30.60.70.712.72.41.51.51.131.41.94.62.24.410.42125.830.836.940.160.485.3
00000.30.30.20.400000000.2001.50.500.50.11.81
000000000000000000000000
0.9000000000002.75.79.41514.70000000
1.31.51.511.93.53.532.82.43.858.412.713.520.927.429.635.638.847.547.572.5104.51
00.50.50.5000000002929.324.512.500000000
000000000000000000000000
0000000000000000000.22.30.90.49.110.31
00.50.50.5000000002929.324.512.5000.22.30.90.49.110.31
1.3221.51.93.53.532.82.43.8537.4423833.427.429.635.841.148.447.981.6114.81
00.020.020.010.050.030.010.020.020.020.030.040.10.060.030.050.070.220.340.480.650.831.041.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Corcept Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Corcept Therapeutics's financial health and stability.

Assets

Corcept Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Corcept Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Corcept Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Corcept Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-1-7-18-9-15-20-24-11-20-20-26-32-38-46-31-681297594106112101106
00000000000000000000001,00001,000
000000000000000000-761416144-33-29
000100200-1011-50-501-53-4-5068
0024010124346121414141627455870928890
0000000000000000000000000
0000000000000000000161093947
0-1-5-13-10-13-17-23-11-18-18-22-27-36-37-2731860115136152167120127
00000000000000000000-1-1000
000-31-391525-5230000000-73-90-117-119136-11490
000-31-391525-5230000000-73-90-116-118136-11391
0000000000000000000000000
000000000000029-1-4-9-14-15000000
01261104902181923234259012277-14-2213-2794-139
02271104903181923234289-1-313-7-8-14-2812-302-17-148
---------------------6.00-1.00-22.00-21.00-9.00
0000000000000000000000000
0022-4-8-4-2523901553-38-301611-2010-10441-1169
-0.3-1.5-5.4-13.2-10-13.7-17.2-23.2-11-18.4-18-22.3-27.4-36.2-37.2-27.63.118.260.5115.4135150.8167.4119.9126.9
0000000000000000000000000

Corcept Therapeutics stock margins

The Corcept Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Corcept Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Corcept Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Corcept Therapeutics's sales revenue. A higher gross margin percentage indicates that the Corcept Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Corcept Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Corcept Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Corcept Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Corcept Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Corcept Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Corcept Therapeutics Margin History

Corcept Therapeutics Gross marginCorcept Therapeutics Profit marginCorcept Therapeutics EBIT marginCorcept Therapeutics Profit margin
2029e98.66 %0 %34.88 %
2028e98.66 %43.52 %30.61 %
2027e98.66 %38.36 %25.91 %
2026e98.66 %43.52 %35.48 %
2025e98.66 %30.52 %22.64 %
2024e98.66 %20.05 %20.6 %
202398.66 %22.24 %22 %
202298.66 %28.02 %25.23 %
202198.55 %34.02 %30.74 %
202098.42 %36.22 %29.95 %
201998.21 %36.41 %30.73 %
201897.93 %35.63 %30.02 %
201797.74 %33.23 %81.09 %
201697.54 %12.55 %9.96 %
201597.22 %-6.76 %-12.72 %
201496.62 %-103.76 %-118.05 %
201398.08 %-399.04 %-442.31 %
201296.97 %-1,100 %-1,151.52 %
201198.66 %0 %0 %
201098.66 %0 %0 %
200998.66 %0 %0 %
200898.66 %-9,850 %-10,050 %
200798.66 %-2,440 %-2,320 %
200698.66 %-8,533.33 %-8,300 %
200598.66 %0 %0 %
200498.66 %0 %0 %

Corcept Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Corcept Therapeutics earnings per share therefore indicates how much revenue Corcept Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Corcept Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Corcept Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Corcept Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Corcept Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Corcept Therapeutics Revenue, EBIT and net profit per share

DateCorcept Therapeutics Sales per ShareCorcept Therapeutics EBIT per shareCorcept Therapeutics Earnings per Share
2029e12.97 undefined0 undefined4.52 undefined
2028e10.03 undefined0 undefined3.07 undefined
2027e8.76 undefined0 undefined2.27 undefined
2026e10.88 undefined0 undefined3.86 undefined
2025e7.89 undefined0 undefined1.79 undefined
2024e6.73 undefined0 undefined1.39 undefined
20234.32 undefined0.96 undefined0.95 undefined
20223.46 undefined0.97 undefined0.87 undefined
20212.9 undefined0.99 undefined0.89 undefined
20202.85 undefined1.03 undefined0.85 undefined
20192.5 undefined0.91 undefined0.77 undefined
20181.98 undefined0.71 undefined0.6 undefined
20171.28 undefined0.42 undefined1.04 undefined
20160.7 undefined0.09 undefined0.07 undefined
20150.47 undefined-0.03 undefined-0.06 undefined
20140.26 undefined-0.27 undefined-0.31 undefined
20130.1 undefined-0.42 undefined-0.46 undefined
20120.04 undefined-0.39 undefined-0.41 undefined
20110 undefined-0.39 undefined-0.39 undefined
20100 undefined-0.4 undefined-0.38 undefined
20090 undefined-0.39 undefined-0.39 undefined
20080 undefined-0.42 undefined-0.43 undefined
20070.01 undefined-0.36 undefined-0.34 undefined
20060.01 undefined-1.12 undefined-1.09 undefined
20050 undefined-0.94 undefined-0.89 undefined
20040 undefined-0.87 undefined-0.84 undefined

Corcept Therapeutics business model

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics is one of the most popular companies on Eulerpool.com.

Corcept Therapeutics SWOT Analysis

Strengths

Corcept Therapeutics Inc has several strengths that contribute to its success in the pharmaceutical industry:

  • Strong Product Portfolio: Corcept Therapeutics has a diverse range of patented medications, including Korlym and Cushing's syndrome treatments. This broad product portfolio reduces its dependence on a single product.
  • Market Leadership: The company is one of the leading providers of medications for Cushing's syndrome and has established a strong presence in this niche market. This market leadership provides a competitive edge.
  • Research and Development Capabilities: Corcept Therapeutics invests significantly in R&D, allowing it to develop innovative drugs and explore new therapeutic areas. This focus on research enables the company to stay ahead of its competitors.
  • Effective Marketing and Distribution Channels: The company has established robust marketing and distribution channels, ensuring its products reach healthcare providers and patients efficiently.
  • Strong Financial Performance: Corcept Therapeutics has experienced consistent revenue growth over the years, reflecting its strong financial performance. This stability provides the company with resources for future growth and investment.

Weaknesses

Despite its strengths, Corcept Therapeutics Inc also faces certain weaknesses that pose challenges to its growth and competitiveness:

  • Dependency on Few Products: Despite having a strong product portfolio, the company heavily relies on a few key medications, such as Korlym. This dependency exposes Corcept Therapeutics to the risk of sales fluctuations if demand for these drugs declines.
  • Regulatory Risks: As a pharmaceutical company, Corcept Therapeutics operates in a highly regulated industry. Changes in government regulations or increased scrutiny can impact the company's operations and hinder its ability to bring new medications to market.
  • Limited Global Presence: The company's operations are primarily focused in the United States, which limits its market reach. Expanding into international markets could provide growth opportunities, but it also involves additional complexities and risks.

Opportunities

Corcept Therapeutics Inc can explore various opportunities to further enhance its business and drive future growth:

  • Expansion into New Therapeutic Areas: By leveraging its research capabilities, the company can explore and enter new therapeutic areas to diversify its product offerings and revenue streams.
  • Increasing Awareness: There is an opportunity for Corcept Therapeutics to raise awareness among healthcare providers and patients about its innovative medications, potentially capturing a larger market share.
  • Strategic Partnerships: Collaborating with other pharmaceutical companies or research institutions can enable Corcept Therapeutics to access new technologies, enhance its R&D efforts, or expand its distribution network.
  • Global Market Expansion: Seeking regulatory approvals and entering international markets can broaden the company's customer base and revenue potential.

Threats

Corcept Therapeutics Inc faces certain threats that may impact its business operations and market position:

  • Competition: The pharmaceutical industry is highly competitive, with other companies developing similar medications for various diseases. Increased competition can result in pricing pressures and reduced market share.
  • Potential Patent Challenges: As patents expire, competitors may enter the market with generic alternatives, eroding Corcept Therapeutics' market share and profitability.
  • Healthcare Reforms: Changes in healthcare policies, reimbursement rates, or insurance coverage can influence the demand and affordability of medications, affecting the company's financial performance.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Corcept Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Corcept Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Corcept Therapeutics shares outstanding

The number of shares was Corcept Therapeutics in 2023 — This indicates how many shares 111.742 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Corcept Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Corcept Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Corcept Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Corcept Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Corcept Therapeutics.

Corcept Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.29 0.41  (42.56 %)2024 Q3
6/30/20240.23 0.32  (36.4 %)2024 Q2
3/31/20240.22 0.25  (11.41 %)2024 Q1
12/31/20230.26 0.28  (6.38 %)2023 Q4
9/30/20230.22 0.28  (25.73 %)2023 Q3
6/30/20230.15 0.25  (63.4 %)2023 Q2
3/31/20230.2 0.14  (-29.01 %)2023 Q1
12/31/20220.23 0.14  (-39 %)2022 Q4
9/30/20220.23 0.3  (30.72 %)2022 Q3
6/30/20220.24 0.24  (0.13 %)2022 Q2
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Corcept Therapeutics stock

Eulerpool World ESG Rating (EESG©)

32/ 100

🌱 Environment

4

👫 Social

23

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Corcept Therapeutics shareholders

%
Name
Stocks
Change
Date
13.23419 % BlackRock Institutional Trust Company, N.A.13,866,788-233,9036/30/2024
9.09853 % The Vanguard Group, Inc.9,533,441-13,9576/30/2024
7.86229 % Ingalls & Snyder LLC (Asset Management)8,238,106-65,0416/30/2024
6.59722 % Renaissance Technologies LLC6,912,571-205,8006/30/2024
5.06795 % Baker (George Leonard Jr.)5,310,19604/5/2024
3.64169 % Parallel Advisors, LLC3,815,760836/30/2024
3.33973 % State Street Global Advisors (US)3,499,370-76,1566/30/2024
2.88446 % Belanoff (Joseph K)3,022,335190,4177/31/2024
2.55424 % Dimensional Fund Advisors, L.P.2,676,335108,6586/30/2024
2.30136 % Novo Holdings A/S2,411,36209/30/2024
1
2
3
4
5
...
10

Corcept Therapeutics Executives and Management Board

Dr. Joseph Belanoff(65)
Corcept Therapeutics President, Chief Executive Officer, Co-Founder, Director (since 1999)
Compensation 7.35 M
Mr. Sean Maduck(46)
Corcept Therapeutics President - Corcept Endocrinology (since 2022)
Compensation 3.71 M
Mr. Gary Robb(60)
Corcept Therapeutics Chief Business Officer, Secretary
Compensation 3.2 M
Dr. Hazel Hunt(63)
Corcept Therapeutics Chief Scientific Officer
Compensation 3.11 M
Mr. Atabak Mokari(46)
Corcept Therapeutics Chief Financial Officer, Treasurer
Compensation 1.89 M
1
2
3
4

Most common questions regarding Corcept Therapeutics

What values and corporate philosophy does Corcept Therapeutics represent?

Corcept Therapeutics Inc represents values of innovation, dedication, and patient-centric approach. As a biopharmaceutical company, Corcept is committed to developing innovative medications to improve patient lives. Their corporate philosophy revolves around the belief that patients are at the heart of what they do, and they strive to address unmet medical needs. Corcept Therapeutics Inc employs cutting-edge scientific research and partnerships to create effective therapies for serious disorders, including Cushing's syndrome. With a focus on scientific excellence, patient well-being, and dedication to improving healthcare outcomes, Corcept Therapeutics Inc stands out in the biopharmaceutical industry. Keep up with the latest developments and news regarding Corcept Therapeutics Inc on our website.

In which countries and regions is Corcept Therapeutics primarily present?

Corcept Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Corcept Therapeutics achieved?

Corcept Therapeutics Inc has achieved significant milestones in its history. One notable achievement is the approval and commercialization of its flagship drug, Korlym, by the U.S. Food and Drug Administration (FDA). This medication is used to treat patients with Cushing's syndrome, a rare and severe endocrine disorder. Additionally, Corcept has successfully expanded the approved indications for Korlym to include the treatment of patients with hyperglycemia secondary to Cushing's syndrome. The company has also completed several clinical trials, demonstrating the efficacy and safety of its products. Overall, Corcept Therapeutics Inc has made remarkable strides in advancing the field of endocrinology with its innovative treatments.

What is the history and background of the company Corcept Therapeutics?

Corcept Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. Founded in 1998, Corcept has its headquarters in Menlo Park, California. The company's flagship product, Korlym, is an FDA-approved medication for patients with Cushing's syndrome. Corcept's focus on cortisol-related disorders has led to the exploration of additional treatment indications. With a dedicated research and development team, Corcept Therapeutics Inc continues to innovate in the field of endocrinology and neurobiology, striving to improve patients' lives worldwide.

Who are the main competitors of Corcept Therapeutics in the market?

The main competitors of Corcept Therapeutics Inc in the market are pharmaceutical companies such as Novartis, Pfizer, and Eli Lilly and Company.

In which industries is Corcept Therapeutics primarily active?

Corcept Therapeutics Inc is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Corcept Therapeutics?

The business model of Corcept Therapeutics Inc. revolves around developing, manufacturing, and commercializing drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. As a pharmaceutical company, Corcept focuses on discovering innovative therapies to address unmet medical needs. With a particular emphasis on the research and development of selective cortisol modulators, the company aims to provide effective solutions for patients suffering from disorders caused by the excess production of cortisol. Corcept Therapeutics Inc. aims to improve patient outcomes by harnessing its expertise in the field of selective cortisol modulation and delivering innovative medical therapies.

What is the P/E ratio of Corcept Therapeutics 2024?

The Corcept Therapeutics P/E ratio is 40.47.

What is the P/S ratio of Corcept Therapeutics 2024?

The Corcept Therapeutics P/S ratio is 8.34.

What is the Quality Investing of Corcept Therapeutics?

The Quality Investing for Corcept Therapeutics is 6/10.

What is the revenue of Corcept Therapeutics 2024?

The expected Corcept Therapeutics revenue is 705.67 M USD.

How high is the profit of Corcept Therapeutics 2024?

The expected Corcept Therapeutics profit is 145.35 M USD.

What is the business model of Corcept Therapeutics

Corcept Therapeutics Inc is a pharmaceutical company focused on the development of medications to treat serious diseases such as Cushing's syndrome and solid tumors. The company operates in three business segments: (1) medication development and commercialization, (2) clinical studies, and (3) licensing fees from third-party companies. Corcept develops medications that block cortisol receptors, such as Korlym for treating Cushing's syndrome. They also conduct clinical studies to further develop and prove the efficacy of their medications. Additionally, the company generates revenue through licensing agreements with third-party companies. Corcept has established partnerships with IBSA Pharma and Teva Pharmaceutical Industries to market Korlym in Europe and Israel. Overall, Corcept focuses on addressing medical challenges, aligning its business segments, and advancing the clinical development of its products. It has become a leading company in this field through its specialization in a specific disease and the development of drugs to treat it. Collaborations and a strong focus on clinical research have contributed to Corcept's sustainable business model aimed at long-term growth and success in improving healthcare. The company's wide range of products is tailored to its core competencies and supports its comprehensive healthcare model.

What is the Corcept Therapeutics dividend?

Corcept Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Corcept Therapeutics pay dividends?

The dividend cannot currently be calculated for Corcept Therapeutics or the company does not pay out a dividend.

What is the Corcept Therapeutics ISIN?

The ISIN of Corcept Therapeutics is US2183521028.

What is the Corcept Therapeutics WKN?

The WKN of Corcept Therapeutics is 529882.

What is the Corcept Therapeutics ticker?

The ticker of Corcept Therapeutics is CORT.

How much dividend does Corcept Therapeutics pay?

Over the past 12 months, Corcept Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corcept Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Corcept Therapeutics?

The current dividend yield of Corcept Therapeutics is .

When does Corcept Therapeutics pay dividends?

Corcept Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corcept Therapeutics?

Corcept Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Corcept Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corcept Therapeutics located?

Corcept Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corcept Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corcept Therapeutics from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Corcept Therapeutics pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Corcept Therapeutics in the year 2023?

In the year 2023, Corcept Therapeutics distributed 0 USD as dividends.

In which currency does Corcept Therapeutics pay out the dividend?

The dividends of Corcept Therapeutics are distributed in USD.

All fundamentals about Corcept Therapeutics

Our stock analysis for Corcept Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corcept Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.